21
Participants
Start Date
February 26, 2018
Primary Completion Date
April 16, 2020
Study Completion Date
August 26, 2023
APL-2
APL-2 administered as a daily subcutaneous infusion for 48 weeks
Davita Clinical Research, The Bronx
Westchester Medical Center, Valhalla
Washington Nephrology Associates, Washington D.C.
Washington Nephrology Associates, Takoma Park
Washington Nephrology Associates, Alexandria
Davita Clinical Research, Chesapeake
Southeastern Nephrology Associates, Wilmington
Emory University, Atlanta
Horizon Research Group, Coral Gables
University Clinical Health, Memphis
American Research LLC, Jeffersonville
Milwaukee Nephrologists, Wauwatosa
Clinical Research Consultants, Kansas City
Northwest Louisiana Nephrology LLC, Shreveport
Children's Hospital Colorado, Aurora
HealthONE Physician Care, Rocky Mountain Hospital for Children, Denver
Stanford University, Stanford
Lead Sponsor
Apellis Pharmaceuticals, Inc.
INDUSTRY